DUBLIN, Ireland – Global leader in the use of artificial intelligence to discover new drugs announces a new US head office based in Boston and the associated appointment of two key new executives, veteran biopharma executive Arthur Hiller and Tim Considine from Recursion Pharma. This new office will expand to lead US Operations including corporate development, strategic activities and initiatives as Nuritas continues its significant growth trajectory.
Mr. Arthur Hiller – Chief Corporate Development Officer
Mr. Hiller joins Nuritas to help drive expansion plans globally and further develop its offering into the biopharma and drug discovery space, where it is already developing a pipeline of products targeted at treatment of oncologic, metabolic and cardiovascular disease.
Hiller holds a bachelor’s degree in journalism from Northwestern University and a Master’s Degree in Business Policy from Columbia University, serves as Lecturer and faculty member of the Healthcare Ventures class and the IMPACT Innovation program at MIT, and in Advisory Board, fundraising, and business development capacities for a wide range of start-up and early stage companies in the Boston area.
Earlier in his career, Arthur served as CEO of two early-stage life sciences companies. During that period, he successfully sold one of the companies to the division of a Fortune 1000 company, raised Series B-round funding, and built high-performing, successful teams. Prior to these roles, Arthur held executive positions in general management, marketing, sales, sales management, and business development at Millennium Pharmaceuticals, Inc., Merck and Co, and two other large, multinational pharmaceutical companies.
Dr Nora Khaldi, Founder and Chief Scientific Officer of Nuritas said: “We’re tremendously excited to have Arthur on board with us. The depth of his experience in the pharma and biotech industries make him the perfect fit for Nuritas. We know that the technology platform we have developed at Nuritas has the potential to be paradigm-shifting, and with Arthur on the team, we will be better able to identify partnership opportunities that support our pipeline and apply our technology to capture some of the most significant challenges in drug discovery today.”
Hiller says: “Partnership and development are in my DNA and in my role as Chief Corporate Development Officer, I will focus on ensuring that our discovery engine is focused on creating a pipeline that meets the criteria for novelty and commercial opportunity consistent with the needs of biopharma partners, as well as the needs of industry and academic collaborators who are interested in integrating these capabilities into their existing discovery tools.”
Mr. Tim Considine – Chief Strategy Officer
Nuritas has also appointed Tim Considine JD to the newly created role of Chief Strategy Officer, effective immediately. As Chief Strategy Officer, Tim will join the executive team to help lead overall value creation for Nuritas through deeply aligning the company’s science with commercial market requirements via the design and implementation of a full strategic development plan. He will have a key focus on integration internally and externally to help ensure that Nuritas is the chosen partner for accelerated drug discovery.
“Tim’s experience and in-depth knowledge of these key areas will help ensure that the Nuritas platform is primely positioned and clearly driven to support market, customer and ultimately patient needs,” said Emmet Browne, Chief Executive Officer of Nuritas. “We are delighted to have individuals of such strength and ability on board as we continue on our mission to improve the lives of billions of people worldwide.”
Mr. Considine has over 25 years’ experience in various drug development, strategic planning, legal and business development roles. Prior to joining Nuritas, Mr. Considine most recently served as Senior Vice President of Strategic Development at Recursion Pharmaceuticals, a privately held AI-enabled drug discovery company. At Recursion, Tim was a key contributor to the rapid growth of the company, led the company’s drug development programs bringing the company’s first compounds into the clinic, and previously served as Vice President of Business Development, Corporate Counsel, and IP Counsel. Mr. Considine also brings considerable therapeutic protein development experience to the company having worked extensively on parathyroid hormone and GLP-2 programs as head of Clinical Operations at NPS Pharmaceuticals. Mr. Considine received a B.Sc. (Hons.) in Pharmacology from University College Dublin, and a J.D. with highest honours, from the S.J. Quinney School of Law at the University of Utah.
Considine said “I am very pleased to join Nuritas at what I believe is the beginning of a golden age of the application of technology to biology that will allow us to re-invent how we, as a society, think about human health. I am particularly excited by the farsighted approach the Nuritas team is taking in exploring how peptides can be used to tackle human disease that goes beyond the traditional approach of post hoc therapeutic intervention and incorporates a more holistic view that includes consideration of disease prevention, diagnosis, nutrition, and health maintenance. I very much look forward to helping the team realise the company’s ambitious and necessary vision.”
Founded in 2014 by mathematician and bioinformatician Dr. Nora Khaldi, Nuritas is the first company in the world to demonstrate that AI can accelerate the discovery of a healthcare product from concept to market in less than 3 years. Nuritas is a discovery platform for active peptides that can prevent or treat disease with industry leading speed and accuracy. It is successfully doing so currently in collaboration with a number of industry leading multinationals. The multi-award winning company is changing the landscape of drug discovery and functional food ingredients by identifying novel peptides using a proprietary artificial intelligence (AI) platform, with in-silico predictions validated by their in-house laboratory and multidisciplinary team of scientists. For more information visit: www.nuritas.com.
AI Applications Summit Biopharma – Boston, Nov 11, 2019 Coinciding with the announcement of our US head office in Boston, Dr Nora Khaldi will be on the Innovation Spotlight Changemaker Panel at the AI Applications Summit.
Press Kit available for download here.
Media Contact: Audrey Wall, Nuritas +35314301290, firstname.lastname@example.org